Literature DB >> 30003596

Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?

Gaétan Gentile1,2, Maeva Jego1,3, Michel Spadari2,4, Karolina Griffiths1, Emilie Jouanjus5,6, Joëlle Micallef2,4.   

Abstract

Addictovigilance is a health vigilance dedicated to the survey of medicinal or illicit psychoactive substance use disorders (SUDs). France is the only European country to have a vigilance system specifically dedicated to substances with an abuse/addiction potential. The French Addictovigilance system is organized in a network of regional tertiary centres (called Abuse and Dependence Monitoring Centres, CEIP-Addictovigilance) and works in close collaboration with Regional and National health authorities. Because of the essential and unavoidable nature of their practice in the French Healthcare system, general practitioners (GPs) are key actors to identify and track Addictovigilance signals. They have been involved in several of the pharmacoepidemiological surveys implemented by the French Addictovigilance Network (FAN). Now, they increasingly participate in clinical research projects and studies. In this article, interactions between GPs and the FAN are illustrated with two examples: patients on opioid substitution treatment and patients on opioid analgesics. Collaborations between GPs and the FAN could be further potentiated. In particular, more effective communication on psychoactive SUDs including abuse/addiction is necessary to optimize the implementation of preventive measures for patients on psychoactive substances medications, and to improve the attitudes of GPs and more widely health professionals in the management of any psychoactive user suffering from SUDs. In addition, both adapted training and improved collaborative research could contribute to the optimization (safety, quality) of professional practices.
© 2018 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  Addictovigilance; French Addictovigilance Network; general practice; opiate substitutive treatments; opioid analgesics; primary care; psychoactive substances use disorders

Mesh:

Substances:

Year:  2018        PMID: 30003596     DOI: 10.1111/fcp.12401

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Authors:  Joelle Perri-Plandé; Ghada Miremont-Salamé; Joëlle Micallef; Cameron Herman; Marie Baumevieille; Frédéric Abriat; Maryse Lapeyre-Mestre; Françoise Haramburu; Amélie Daveluy
Journal:  Drug Saf       Date:  2021-10-29       Impact factor: 5.606

2.  Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.

Authors:  Maryse Lapeyre-Mestre
Journal:  Therapie       Date:  2020-09-28       Impact factor: 2.070

3.  Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review.

Authors:  Gaetan Gentile; Maryse Lapeyre-Mestre; Joelle Micallef
Journal:  BJGP Open       Date:  2020-05-01

Review 4.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.